within Pharmacolibrary.Drugs.D_Dermatologicals.D07X_CorticosteroidsOtherCombinations.D07XC04_Diflucortolone;

model Diflucortolone
  extends Pharmacolibrary.Drugs.ATC.D.D07XC04;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>D07XC04</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Diflucortolone is a synthetic corticosteroid with potent anti-inflammatory, antipruritic, and vasoconstrictive properties, primarily used in dermatological practice for the treatment of various inflammatory and allergic skin disorders. The most common form is diflucortolone valerate in topical preparations. It is not widely approved in all countries, with primary use observed in specific regions for external application in humans.</p><h4>Pharmacokinetics</h4><p>No human pharmacokinetic studies for diflucortolone or diflucortolone valerate in literature reporting relevant PK parameters. Parameters below represent rough estimates based on general characteristics of potent topical corticosteroids, not based on direct empirical measurement.</p><h4>References</h4><ol><li><p>Abdel-Salam, FS, et al., &amp; Elkheshen, SA (2017). Nanostructured lipid carriers as semisolid topical delivery formulations for diflucortolone valerate. <i>Journal of liposome research</i> 27(1) 41–55. DOI:<a href=&quot;https://doi.org/10.3109/08982104.2016.1149866&quot;>10.3109/08982104.2016.1149866</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26956098/&quot;>https://pubmed.ncbi.nlm.nih.gov/26956098</a></p></li><li><p>Eroğlu, İ, et al., &amp; Özer, Ö (2016). Effective topical delivery systems for corticosteroids: dermatological and histological evaluations. <i>Drug delivery</i> 23(5) 1502–1513. DOI:<a href=&quot;https://doi.org/10.3109/10717544.2014.960981&quot;>10.3109/10717544.2014.960981</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25259424/&quot;>https://pubmed.ncbi.nlm.nih.gov/25259424</a></p></li><li><p>Täuber, U, et al., &amp; Matthes, H (1993). Does salicylic acid increase the percutaneous absorption of diflucortolone-21-valerate?. <i>Skin pharmacology : the official journal of the Skin Pharmacology Society</i> 6(4) 276–281. DOI:<a href=&quot;https://doi.org/10.1159/000211150&quot;>10.1159/000211150</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8198813/&quot;>https://pubmed.ncbi.nlm.nih.gov/8198813</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Diflucortolone;
